Frank Eldridge
Family · Waycross, GANPI 1467814228
Payments from drug & device makers
Across 355 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Novo Nordisk$914
- Lilly USA, LLC$521
- Amgen$411
- AstraZeneca$331
- Pfizer$318
- plus $3K from 34 others
What the payments were for
- Food & beverage$8,237100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 58 | $2,884 |
| Novo Nordisk | 58 | $914 |
| Lilly USA, LLC | 31 | $521 |
| Amgen | 26 | $411 |
| AstraZeneca | 16 | $331 |
| Pfizer | 17 | $318 |
| Bayer | 12 | $307 |
| AbbVie | 15 | $262 |
| Paratek Pharmaceuticals, Inc. | 11 | $245 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $206 |
| Otsuka America Pharmaceutical, Inc. | 9 | $205 |
| Novartis | 9 | $179 |
| Dexcom, Inc. | 8 | $130 |
| Boehringer Ingelheim | 8 | $130 |
| Merck | 7 | $111 |
| Alkermes, Inc. | 1 | $100 |
| Abbott | 5 | $83 |
| E.r. Squibb & Sons, L.L.C. | 5 | $81 |
| Astellas Pharma US Inc | 4 | $79 |
| Corium, LLC | 3 | $73 |
| Exact Sciences | 4 | $72 |
| Antares Pharma, Inc. | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Johnson & Johnson | 4 | $62 |
| Corcept Therapeutics | 3 | $58 |
| GSK | 3 | $51 |
| Sanofi Pasteur Inc. | 3 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $24 |
| IBSA Pharma Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Neurelis, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WaveWriter Alpha Prime 16$946
- LYBALVI$400
- NA$128
- NUZYRA$125
- Kerendia$125
- GENERAL PAIN MANAGEMENT$123
- WAVEWRITER ALPHA$109
- RYBELSUS$100
- MOUNJARO$100
How this compares
$8,237 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $95,568 |
| MounjaroTirzepatide | 64 | $93,072 |
| FarxigaDapagliflozin Propanediol | 27 | $34,808 |
| RybelsusSemaglutide | 11 | $32,094 |
| Zileuton ErZileuton | 11 | $27,484 |
| LinzessLinaclotide | 25 | $26,373 |
| EliquisApixaban | 20 | $23,468 |
| JardianceEmpagliflozin | 17 | $18,701 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,554 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,256 |
| Testosterone Cypionate | 83 | $4,674 |
| LevemirInsulin Detemir | 13 | $2,227 |
| Ondansetron Hcl | 11 | $1,995 |
| Mometasone Furoate | 18 | $1,832 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Levemir | $914 | $129,88992 claims |
| Lilly USA, LLCMounjaro | $521 | $93,07264 claims |
| AstraZenecaFarxiga | $331 | $34,80827 claims |
| AbbVieLinzess | $262 | $26,37325 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $130 | $24,95630 claims |
| PfizerEliquis | $318 | $23,46820 claims |
| GSKTrelegy Ellipta | $51 | $11,55416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Waycross
- Hannah BanachWaycross$85K
- Tiffany HarkleroadWaycross$16K
- Morgan EldridgeWaycross$15K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Morgan GroothandEvans$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.